144 related articles for article (PubMed ID: 30735922)
1. Rates and predictors of one-year antipsychotic treatment discontinuation in first-episode schizophrenia: Results from an open-label, randomized, "real world" clinical trial.
Cheng Z; Yuan Y; Han X; Yang L; Zeng X; Yang F; Lu Z; Wang C; Deng H; Zhao J; Xiang YT; Correll CU; Yu X
Psychiatry Res; 2019 Mar; 273():631-640. PubMed ID: 30735922
[TBL] [Abstract][Full Text] [Related]
2. Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments (SMART-CAT) in first-episode schizophrenia patients: Rationale and trial design.
Li X; Guo X; Fan X; Feng T; Wang C; Yao Z; Xu X; Chen Z; Wang H; Xie S; He J; Zhuo K; Xiang Q; Cen H; Wang J; Smith RC; Jin H; Keshavan MS; Marder SR; Davis JM; Jiang K; Xu Y; Liu D
Schizophr Res; 2021 Apr; 230():87-94. PubMed ID: 33279374
[TBL] [Abstract][Full Text] [Related]
3. Post-hoc analysis investigating the safety and efficacy of brexpiprazole in Japanese patients with schizophrenia who were switched from other antipsychotics in a long-term study (Secondary Publication).
Ishigooka J; Usami T; Iwashita S; Kojima Y; Matsuo S
Neuropsychopharmacol Rep; 2020 Jun; 40(2):122-129. PubMed ID: 32297486
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with discontinuation of aripiprazole treatment after switching from other antipsychotics in patients with chronic schizophrenia: A prospective observational study.
Takaesu Y; Kishimoto T; Murakoshi A; Takahashi N; Inoue Y
Psychiatry Res; 2016 Feb; 236():71-74. PubMed ID: 26743338
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching.
Agid O; Schulze L; Arenovich T; Sajeev G; McDonald K; Foussias G; Fervaha G; Remington G
Eur Neuropsychopharmacol; 2013 Sep; 23(9):1017-22. PubMed ID: 23706529
[TBL] [Abstract][Full Text] [Related]
6. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study.
Perkins DO; Gu H; Weiden PJ; McEvoy JP; Hamer RM; Lieberman JA;
J Clin Psychiatry; 2008 Jan; 69(1):106-13. PubMed ID: 18312044
[TBL] [Abstract][Full Text] [Related]
7. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
[TBL] [Abstract][Full Text] [Related]
8. Randomised controlled trial of gradual antipsychotic reduction and discontinuation in people with schizophrenia and related disorders: the RADAR trial (Research into Antipsychotic Discontinuation and Reduction).
Moncrieff J; Lewis G; Freemantle N; Johnson S; Barnes TRE; Morant N; Pinfold V; Hunter R; Kent LJ; Smith R; Darton K; Horne R; Crellin NE; Cooper RE; Marston L; Priebe S
BMJ Open; 2019 Nov; 9(11):e030912. PubMed ID: 31780589
[TBL] [Abstract][Full Text] [Related]
9. Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study.
Haro JM; Novick D; Suarez D; Roca M
J Psychiatr Res; 2009 Jan; 43(3):265-73. PubMed ID: 18644606
[TBL] [Abstract][Full Text] [Related]
10. A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia.
Weiden PJ; Citrome L; Alva G; Brams M; Glick ID; Jackson R; Mattingly G; Kianifard F; Meng X; Pestreich L; Hochfeld M; Winseck A
Schizophr Res; 2014 Mar; 153(1-3):160-8. PubMed ID: 24529610
[TBL] [Abstract][Full Text] [Related]
11. Predictors of discontinuation of antipsychotic medication and subsequent outcomes in the European First Episode Schizophrenia Trial (EUFEST).
Landolt K; Rössler W; Ajdacic-Gross V; Derks EM; Libiger J; Kahn RS; Fleischhacker WW;
Schizophr Res; 2016 Apr; 172(1-3):145-51. PubMed ID: 26922655
[TBL] [Abstract][Full Text] [Related]
12. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.
Suzuki T; Uchida H; Watanabe K; Nomura K; Takeuchi H; Tomita M; Tsunoda K; Nio S; Den R; Manki H; Tanabe A; Yagi G; Kashima H
Psychopharmacology (Berl); 2007 Dec; 195(2):285-95. PubMed ID: 17701027
[TBL] [Abstract][Full Text] [Related]
13. TAILOR - tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial.
Stürup AE; Jensen HD; Dolmer S; Birk M; Albert N; Nielsen M; Hjorthøj C; Eplov L; Ebdrup BH; Mors O; Nordentoft M
Trials; 2017 Sep; 18(1):445. PubMed ID: 28962668
[TBL] [Abstract][Full Text] [Related]
14. Relapse rates following antipsychotic discontinuation in the maintenance phase after first-episode of schizophrenia: Results of a long-term follow-up study.
Üçok A; Kara İA
Schizophr Res; 2020 Nov; 225():31-38. PubMed ID: 31653578
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of Antipsychotic Drugs for 24-Month Maintenance Treatment in First-Episode Schizophrenia: Evidence From a Community-Based "Real-World" Study.
Zhang C; Chen MJ; Wu GJ; Wang ZW; Rao SZ; Zhang Y; Yi ZH; Yang WM; Gao KM; Song LS
J Clin Psychiatry; 2016 Nov; 77(11):e1460-e1466. PubMed ID: 28076667
[TBL] [Abstract][Full Text] [Related]
16. Switching to Clozapine Using Immediate Versus Gradual Antipsychotic Discontinuation: A Pilot, Double-Blind, Randomized Controlled Trial.
Takeuchi H; Lee J; Fervaha G; Foussias G; Agid O; Remington G
J Clin Psychiatry; 2017 Feb; 78(2):223-228. PubMed ID: 28234436
[TBL] [Abstract][Full Text] [Related]
17. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
Schreiner A; Caspi A; Bergmans P; Cherubin P; Keim S; Lara E; Pinchuk I; Schuepbach D; Suleman S; Hargarter L
Psychopharmacology (Berl); 2017 Jan; 234(1):3-13. PubMed ID: 27815602
[TBL] [Abstract][Full Text] [Related]
18. Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data.
Yan T; Greene M; Chang E; Hartry A; Touya M; Broder MS
Adv Ther; 2018 Oct; 35(10):1612-1625. PubMed ID: 30206822
[TBL] [Abstract][Full Text] [Related]
19. Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? A nationwide study in Hungary.
Katona L; Czobor P; Bitter I
Schizophr Res; 2014 Jan; 152(1):246-54. PubMed ID: 24275583
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK;
Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
